LAS VEGAS, Nev.--(BUSINESS WIRE)--During the scientific sessions at the 16 th Annual NANS Conference, Dr. Liong Liem, Anesthesiologist at Sint Antonius Ziekenhuis in the Netherlands and member of the ...
The MarketWatch News Department was not involved in the creation of this content. Real-time insights reveal BIOTRONIK Neuro's remote monitoring with remote programming led to high rates of therapy use ...
We’ve long viewed neuromodulation as a field that offered great promise but faced meaningful challenges to realizing that potential. Thanks to a spurt in innovation in spinal cord stimulation--the ...
Spinal cord stimulation (SCS) to treat pain in persons with multiple sclerosis (MS) was the focus of a recent literature review out of Italy. An analysis from Italy of 7 studies that investigated ...
Protégé upgradeable neurostimulator from St. Jude Medical is the world’s smallest, longest-lasting rechargeable device to treat chronic pain SCS system is designed to be non-invasively upgraded to ...
Abbott announced new five-year data demonstrating that its neuromodulation therapies, including its proprietary BurstDR spinal cord stimulation (SCS) waveform and dorsal root ganglion stimulation ...
Medtronic plc MDT announced a major regulatory advancement in the fast-growing neuromodulation space. Per the announcement, the company received revised commercial labeling approval from the FDA for ...
Boston Scientific has shared a range of data highlighting the benefits of spinal cord stimulation (SCS) therapies within its neuromodulation portfolio. The medtech giant presented a total of 17 ...
Introduction: Spinal cord stimulation (SCS) is a well-established and accepted treatment for chronic neuropathic, nociplastic (neuropathic-like) and ischemic pain. The heterogeneity of patients in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results